BioXcel Therapeutics Inc Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : On the price you announced, it's a little lower, I think, than some might have anticipated. Is there any additional color you can give on your assumptions around what market penetration could be at this price point?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : I have a few here, a couple on pricing and then one on data. So now that you've priced for access, do you have any updates on the number of treatments per year per patient and the approved indication and in Alzheimer's agitation? There's not necessarily retreatments for the same episode.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : And on the price, was this a specific or exact price that was used in setting the milestones and royalties in your latest financing agreement?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Got it. Could you provide any color around that? Was it higher? Or any sort of color you could provide around that would be helpful.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Got it. And then how would you wait the relative contribution of pricing for access to ensure success for your potentially broad range of indications versus pushback from hospitals or payers that made you arrive at this pricing decision? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 09, 2022 / 12:30PM, BTAI.OQ - Q1 2022 BioXcel Therapeutics Inc Earnings Call

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Got it. And then my last question, when can we expect to see the data on the 40-microgram dose in the Alzheimer's agitation trial?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on the progress. I guess another one just on the pricing. I've heard your responses. It just -- I'm somewhat confused. I guess we were all in the similar ballpark just based on discussions with you prior to the launch. And then I just -- I'm curious what is the specific pushback here from payers and institutions that ultimately that what is quite a significantly lower price? And then just also on the IGALMI operational structure, can you provide any guide on when this will become a cash flow positive operation either from a timing perspective, number of patients treated perspective, market share perspective, anything there would be helpful. And then just my final question is on OnkosXcel, again, could you just walk us through the strategy there? I know you kind of -- you alluded to it before, but how do you plan to split resources, both financial and human. Any help there would be helpful.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. Great. Maybe on the operational structure in 701?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. And then just on the metrics to achieve profitability with IGALMI, just help us out there? And is this -- are you -- are you confident you can get there with the current indication? Or do we need to see an expanded label? Just any thoughts there would be helpful.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. Great. And actually, one last one before I'll jump off. But how trackable will this be from our point of view using third-party data? Any help there?

Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So I just wanted to know between the 2 doses of 10 and 180-microgram as per your internal sort of projections, like do you think 1 dose might be stocked higher by hospitals than the other?

Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Okay. And then I just had a follow-up on the reimbursement. Is there like a time line when you might be when we can expect this listen to be established?

Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Great. And then the last one, sorry if I missed that in terms for OnkosXcel, would you be providing some updates later in the year about how you plan to have the financial and operational resources.